A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

Inclusion Criteria: * Patients with a definite diagnosis of Diffuse large B-cell lymphoma(DLBCL) * Patients who have received at least initial standard treatment * Patients with measurable lesions (based on International Working Group \[IWG\] 2014 criteria) * Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1 \<Only for dose-expansion stage\> * Patients who are pathologically diagnosed as CD20 positive lymphoma * Patients who have a history of being treated with 1 to 5 regimens of previous chemotherapy for the underlying disease Exclusion Criteria: * Patients who are candidates for autologous or allogeneic hematopoietic stem cell transplantation * Patients who were refractory to initial standard treatment * Patients who have a history of bendamustine administration and are intolerant to bendamustine * Patients with central nervous system (CNS) involvement of lymphoma or with a history of CNS involvement of lymphoma * Patients diagnosed with DLBCL transformed from low-grade B-cell non-Hodgkin's lymphoma (NHL) \<Only for dose-expansion stage\> \- Patients who have a history of rituximab administration and are intolerant to rituximab